Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter
Sl No Brand Q1 H1 9M Total 1 Johnson and Johnson $24.0 2 Eli Lilly $19.8 3 Roche $18.8 4 AstraZeneca $15.3 5 Novo Nordisk $15.2 6 AbbVie $15.0 7 Pfizer $14.4 8 Merck $14.3 9 Novartis $13.1 10 Sanofi $12.4 Top pharmaceutical companies by revenues | 2026 JOHNSON AND JOHNSON Q1 REVENUES: In the first quarter of 2026, the company reported total sales of $24.1 billion, reflecting a 9.9% increase. Revenue from Innovative Medicines reached $15.4 billion. Global operational sales in
Digestive Disease Week | 2026 | News | Updates | iPharmaCenter
AbbVie Showcases New Real-World IBD Data for Skyrizi and Rinvoq at DDW 2026 AbbVie’s latest inflammatory bowel disease (IBD) data package from Digestive Disease Week (DDW) 2026 underscores the growing clinical role of Skyrizi (risankizumab) and Rinvoq (upadacitinib) in Crohn’s disease and ulcerative colitis. Real-world results from the ASPIRE-CD study showed that adults with moderately to severely active Crohn’s disease treated with risankizumab achieved rapid and sustained r
Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss | iPharmaCenter
The U.S. FDA has approved Foundayo (orforglipron), a once‑daily GLP‑1 tablet for chronic weight management in adults with obesity or overweight and weight‑related comorbidities. It is currently the only GLP‑1 pill for weight loss that can be taken at any time of day without specific restrictions on food or water intake. Also read: New Hope for GVHD Patients as Rezurock Wins EU Approval Backed by the phase 3 ATTAIN programme, Foundayo delivered clinically meaningful and sustai
New Hope for GVHD Patients as Rezurock Wins EU Approval | iPharmaCenter
The European Commission has granted conditional marketing authorisation for Sanofi’s Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD) in adults and adolescents aged 12 years and older who weigh at least 40 kg. The approval offers a critical treatment option for patients who have limited benefit from current therapies or have exhausted existing options. Also read: Top 10 Pharmaceutical Companies by Revenue 2025 The decision is supported by evidence from
Bimzelx Outperforms Skyrizi in Head-to-Head Psoriatic Arthritis Trial, Strengthening the Position of UCB’s Blockbuster Bimzelx | iPharmaCenter
Bimzelx (bimekizumab) showed marked superiority over Skyrizi (risankizumab) in improving symptoms of active psoriatic arthritis, achieving statistically significant results at Week 16 as measured by the ACR50 response. This marks the first time a licensed biologic therapy has shown clear superiority over an IL-23 inhibitor in psoriatic arthritis. BE BOLD represents the fourth head-to-head study within the Bimzelx clinical program to demonstrate superior outcomes in psoriatic
European Association of Urology (EAU) 2026 Annual Meeting | News | Updates | iPharmaCenter
Johnson & Johnson Reports Encouraging Early Results for Erda‑iDRS in Intermediate‑Risk Non-Muscle Invasive Bladder Cancer Johnson & Johnson unveiled promising data from a Phase 1, open-label, multicenter clinical trial investigating its novel intravesical drug-release system containing erdafitinib (known as Erda‑iDRS, formerly TAR‑210) in patients with intermediate‑ and high‑risk non–muscle‑invasive bladder cancer (NMIBC) whose tumors carry specific FGFR (fibroblast growth fa